BioCardia takes a new and comprehensive approach to heart failure

We are a clinical-stage regenerative medicine company developing novel therapies to improve the lives of patients suffering from cardiovascular diseases with large unmet medical needs.

Read More

Discover us

Financials & Filings

Review our corporate financial reports and SEC filings

Press Releases

Read about our latest company milestones

Clinical Trials

Complete Questionnaire to find out if you or a loved one qulifies for our CardiAMP Heart Failure Study

Product Pipeline

Learn about our product development programs and obtain an at-a-glance view of their current status

Products

Helix Biotherapeutic Delivery System

AVANCE Steerable Introducer

News

01 Dec

Empowered Patient Podcast

Optimizing Autologous Cell Therapy to Treat Cardiovascular Disease with Dr. Peter Altman
Read More
29 Oct

UW Health

UW Health Treats First Patient in U.S. with Investigational Cell Therapy for Heart Disease
Read More
29 Oct

Greenbay CBS

Neenah musician, educator pursues dream after being first in the world to undergo ‘Investigational Cell Therapy’
Read More
29 Oct

WBay.com

Neenah man gets new lease on life after trial heart procedure
Read More
04 Mar

Henry Ford Health System

Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms
Read More
08 Feb

Cell & Gene

Inside BioCardia's CardiAMP Cell Therapy
Read More
15 Sep

BioTuesdays

BioCardia developing autologous and allogenic cardiovascular cell therapies
Read More
03 Aug

Pharmaceutical Technology

BioCardia’s novel CardiAMP stem cell therapy closer to approval in heart failure
Read More
28 Jul

The Big Biz show

The Big Biz Show interviews BioCardia CEO, Peter Altman
Read More

press releases

10 Jan
2022 BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference
15 Dec
2021 BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates
10 Nov
2021 BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights
08 Nov
2021 BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021
21 Oct
2021 BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia
12 Oct
2021 BioCardia Issued New U.S. Patent for Technology that Enhances Control for Interventional Catheter Based Therapies
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS